[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562294":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":57,"collaborators":20,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":20,"enrollmentInfo":70,"targetDuration":20,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SAbR with Intratumoral STING agonist IMSA101 and IO with Anti-PD1","EXPERIMENTAL","Only one arm will be maintained in this phase II study with all patients undergoing the following treatment:\n\nSOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: three intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C2D1, C3D1)",[13],"Drug: IMSA101",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","IMSA101","All enrolled patients to undergo the following treatment:\n\nSOC treatment: Nivolumab 480mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: three intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C2D1, C3D1)",[9],null,[22],{"name":23,"affiliation":5,"role":24},"RAQUIBUL HANNAN, MD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"SARAH NEUFELD, MANAGER OF CLINICAL RESEARCH, MS, MBA","CONTACT","214 648 1836","Sarah.Hardee@UTSouthwestern.edu",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"RAQUIBUL HANNAN, MD, PhD.","214 645 7696","Raquibul.Hannan@UTSouthwestern.edu",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Dallas","Texas","75390","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-96.80667,32.78306,{"lat":47,"lon":46},[50,54,56],{"name":51,"role":28,"phone":52,"phoneExt":20,"email":53},"BUSAYO ADEFALUJO, CLINICAL RESEARCH COORDINATOR","214 648 1873","Busayo.Adefalujo@UTSouthwestern.edu",{"name":55,"role":28,"phone":29,"phoneExt":20,"email":30},"SARAH NEUFELD SUPERVISOR OF CLINICAL RESEARCH, MS, MBA",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Raquibul Hannan","MD","100562294","phase-2-radiotherapy-in-combination-with-checkpoint-inhibition-for-patients-with-metastatic-kidney-cancer-100562294",false,"NCT06601296","Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer","STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer.","SPARK","Inclusion Criteria:\n\n* Patients must have metastatic ccRCC.\n* Patients must have oligoprogression defined as progression in ≤5 lesions.\n* All oligoprogression lesions must be suitable for radiation.\n* Patients must have at least one site of disease that can be safely injected with IMSA101.\n* Karnofsky Performance Status (KPS) of at least 50%.\n* Age ≥ 18 years.\n* Patients must have adequate organ and marrow function within 14 days prior to study entry.\n* All IMDC risk categories are allowed.\n\nExclusion Criteria:\n\n* Patients with progressive ultracentral\u002Fcentral chest lesions will be excluded","ALL","18 Years",{"count":71,"type":72},15,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR\u002FPULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).",[78,79],"Metastatic Renal Cell Carcinoma ( mRCC)","OligoProgressive Metastatic Disease",[81,82,83,84,85,86,87,88,66,89,90],"renal","kidney","mrcc","metastatic","cancer","STING","PULSAR","SABr","nivolumab","IMSA 101","2025-11-07",{"date":93,"type":94},"2025-11-12","ACTUAL",{"date":96,"type":94},"2025-04-01",{"date":98,"type":72},"2028-10",{"name":5,"class":6},1]